相似文献
1
Translational research in endocrine surgery.
Surg Oncol Clin N Am. 2013 Oct;22(4):857-84. doi: 10.1016/j.soc.2013.06.012. Epub 2013 Jul 26.
2
[Current operative techniques and strategies in endocrine surgery].
Ther Umsch. 2011 Jun;68(6):279-83. doi: 10.1024/0040-5930/a000165.
3
What's new in general surgery: endocrine surgery.
J Am Coll Surg. 2002 Sep;195(3):364-71. doi: 10.1016/s1072-7515(02)01307-8.
4
Endocrine surgery.
Surg Clin North Am. 2014 Jun;94(3):xv-xvi. doi: 10.1016/j.suc.2014.04.001.
5
Presidential address: a new face for endocrine surgery.
Surgery. 2013 Dec;154(6):1143-5. doi: 10.1016/j.surg.2013.05.041.
6
Endocrine surgery--a 23-hour specialty?
ANZ J Surg. 2009 May;79(5):320-2. doi: 10.1111/j.1445-2197.2009.04460.x.
7
Continued Progress and Advancements in Endocrine Surgery.
Surg Clin North Am. 2024 Aug;104(4):xv-xvi. doi: 10.1016/j.suc.2024.02.018. Epub 2024 Mar 12.
8
Endocrine surgery: current and future issues.
Int J Surg. 2014;12 Suppl 1:S1-2. doi: 10.1016/j.ijsu.2014.05.075. Epub 2014 May 29.
9
[Endocrinologic surgery in change].
Tidsskr Nor Laegeforen. 2007 May 3;127(9):1174.
10
Endocrine surgery.
J Am Coll Surg. 2000 Feb;190(2):129-33. doi: 10.1016/s1072-7515(99)00247-1.
引用本文的文献
1
Development and comparison of novel bioluminescent mouse models of pancreatic neuroendocrine neoplasm metastasis.
Sci Rep. 2021 May 13;11(1):10252. doi: 10.1038/s41598-021-89866-1.
2
The Landmark Series: Management of Small Bowel Neuroendocrine Tumors.
Ann Surg Oncol. 2021 May;28(5):2741-2751. doi: 10.1245/s10434-020-09566-4. Epub 2021 Jan 15.
3
Small Bowel Neuroendocrine Tumors.
Curr Probl Surg. 2020 Dec;57(12):100823. doi: 10.1016/j.cpsurg.2020.100823. Epub 2020 May 15.
4
Surgical Management of Neuroendocrine Tumor Liver Metastases.
Surg Oncol Clin N Am. 2021 Jan;30(1):39-55. doi: 10.1016/j.soc.2020.08.001. Epub 2020 Oct 20.
5
RABL6A inhibits tumor-suppressive PP2A/AKT signaling to drive pancreatic neuroendocrine tumor growth.
J Clin Invest. 2019 Mar 4;129(4):1641-1653. doi: 10.1172/JCI123049.
6
Translational Diagnostics and Therapeutics in Pancreatic Neuroendocrine Tumors.
Clin Cancer Res. 2016 Oct 15;22(20):5022-5029. doi: 10.1158/1078-0432.CCR-16-0435.
7
RABL6A promotes G1-S phase progression and pancreatic neuroendocrine tumor cell proliferation in an Rb1-dependent manner.
Cancer Res. 2014 Nov 15;74(22):6661-70. doi: 10.1158/0008-5472.CAN-13-3742. Epub 2014 Oct 1.
8
Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors.
Clin Exp Metastasis. 2014 Dec;31(8):935-44. doi: 10.1007/s10585-014-9681-2. Epub 2014 Sep 21.
9
Medical management of metastatic medullary thyroid cancer.
Cancer. 2014 Nov 1;120(21):3287-301. doi: 10.1002/cncr.28858. Epub 2014 Jun 18.
10
GIPR expression in gastric and duodenal neuroendocrine tumors.
J Surg Res. 2014 Aug;190(2):587-93. doi: 10.1016/j.jss.2014.01.044. Epub 2014 Jan 29.
本文引用的文献
1
Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors.
Surgery. 2013 Dec;154(6):1206-13; discussion 1214. doi: 10.1016/j.surg.2013.04.052.
2
Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors.
Ann Surg Oncol. 2013 Dec;20 Suppl 3(0 3):S739-S746. doi: 10.1245/s10434-013-3318-6. Epub 2013 Oct 10.
3
New strategies in diagnosing cancer in thyroid nodules: impact of molecular markers.
Clin Cancer Res. 2013 May 1;19(9):2283-8. doi: 10.1158/1078-0432.CCR-12-1253. Epub 2013 Feb 19.
4
Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension.
Nat Genet. 2013 Apr;45(4):440-4, 444e1-2. doi: 10.1038/ng.2550. Epub 2013 Feb 17.
5
BRAF V600E inhibition in anaplastic thyroid cancer.
N Engl J Med. 2013 Feb 14;368(7):684-5. doi: 10.1056/NEJMc1215697.
6
Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
N Engl J Med. 2013 Feb 14;368(7):623-32. doi: 10.1056/NEJMoa1209288.
7
The genetics of neuroendocrine tumors.
Semin Oncol. 2013 Feb;40(1):37-44. doi: 10.1053/j.seminoncol.2012.11.005.
8
The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours.
Eur J Nucl Med Mol Imaging. 2013 May;40(5):800-16. doi: 10.1007/s00259-012-2330-6.
9
Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry.
Eur J Cancer. 2013 May;49(8):1975-83. doi: 10.1016/j.ejca.2012.12.022. Epub 2013 Jan 23.
10
Preclinical rationale for PI3K/Akt/mTOR pathway inhibitors as therapy for epidermal growth factor receptor inhibitor-resistant non-small-cell lung cancer.
Clin Lung Cancer. 2013 Jul;14(4):322-32. doi: 10.1016/j.cllc.2012.12.001. Epub 2013 Jan 16.
Zotero 插件